The Body PRO Covers: The 41st Interscience Conference on Antimicrobial Agents and Chemotherapy

Antiretroviral Therapy I (Poster Session 193)

December 18, 2001

  • Long-Term Effects of Treatment Interruptions: 18-Month Evaluation of a Controlled Trial in >300 HIV-Positive Patients
    Abstract 1910
    Authored by E. Wolf (MUC Research GmbH, Munich, Germany), E. Gersbacher (MUC Research GmbH, Munich, Germany), J. Schardt (MUC Research GmbH, Munich, Germany), S. Mueller (MUC Research GmbH, Munich, Germany), C. Hoffmann (KIS - Curatorium for Immunedeficiency, Munich, Germany), M. Procaccianti (Private Practice, Karlsruhe, Germany), F. Mosthaf (Private Practice, Karlsruhe, Germany), A. Ulmer (Private Practice, Stuttgart, Germany), E. Jaegel-Guedes (KIS - Curatorium for Immunedeficiency, Munich, Germany), H. Jaeger (KIS - Curatorium for Immunedeficiency, Munich, Germany)
    View the original abstract

This is a good follow-up to Dr. Gallant's oral presentation yesterday looking at stopping HIV medications. This is a prospective non-randomized controlled trial of treatment for 18 months. Outcomes measured were CD4, viral load, lipids and AIDS events. There were 115 treatment interruption (TI) patients and 186 controls.

There were no differences found in baseline CD4 viral load or percentage of patients with viral load <50. Mean duration of the first treatment interruption was 5.4 weeks. Twenty-nine percent of the patients had more than one treatment interruption. After one month of treatment interruption a mean change of CD4 of -72 and mean viral load increase of +2.1 log were observed with highly significant statistics, as expected.

When the drugs stop, HIV levels go up and CD4 cells go down. But, interestingly enough, so do other things! Cholesterol declined by 54 and triglycerides by 236, which were both quite significant!

After 18 months, CD4 cells did not change significantly. In patients with undetectable viral load, 66 percent remained undetectable 18 months later, compared to 73 percent of the control patients. Antiretroviral therapy was changed in 47 percent vs. 40 percent, respectively. There was no change in AIDS events.

It appears that stopping medications has a small chance of failing to control the virus again at pre-stopping levels, but these odds are not huge and the cholesterol and triglycerides benefit from some stopping. This is something that clearly needs further study, but stopping medications clearly does not seem to do irreparable harm!

Previous | Next

Tell us what you think of The Body's conference coverage!

This article was provided by It is a part of the publication 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001).

Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.